Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein

US11001622B2 · kind B2 · utility

Assignees

• The Brigham and Women's Hospital, Inc. · US
• The Broad Institute, Inc. · US
• Massachusetts Institute of Technology · US

Inventors

• Vijay K. Kuchroo · Newton, US
• Chao Wang · State College, US
• Aviv Regev · Cambridge, US
• Karthik Shekhar · Cambridge, US

Key dates

• Filing date: Nov 17, 2016
• Grant date: May 11, 2021
• Expiry date: Nov 17, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/20
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described herein are methods for suppressing an immune response in a subject, e.g., a subject with an autoimmune disease, by administering to the subject a therapeutically effective amount of recombinant CD5L, CD5L homodimers and/or CD5L:p40 heterodimers, or nucleic acids encoding any of these. Also described are methods for enhancing an immune response in a subject, e.g., a subject with cancer, infection, or an immune deficiency, by administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds specifically to CD5L, D5L homodimers and/or CD5L:p40 heterodimers, and inhibits their binding to the IL-23 receptor, or inhibits formation of the CD5L homodimer and/or CD5L:p40 heterodimer, or inhibitory nucleic acids that target CD5L and/or p40.